Compare ELTK & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | XLO |
|---|---|---|
| Founded | 1970 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.5M | 56.9M |
| IPO Year | 1998 | 2021 |
| Metric | ELTK | XLO |
|---|---|---|
| Price | $8.15 | $8.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 3.9K | ★ 9.5K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | $16.18 | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | $48.71 | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $7.30 | $0.46 |
| 52 Week High | $11.59 | $9.90 |
| Indicator | ELTK | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 47.21 |
| Support Level | $7.68 | $8.52 |
| Resistance Level | $9.15 | $9.22 |
| Average True Range (ATR) | 0.44 | 0.29 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 42.96 | 53.33 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.